Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Maltodextrin Versus Sugar Water Carbohydrate Loading and Gastric Volume in Geriatric Lower Limb Orthopedic Surgery (CHO-GERIGAS)

16 de noviembre de 2026 actualizado por: Burhan, Udayana University

Comparison of Maltodextrin and Sugar Water Carbohydrate Loading on Gastric Volume in Geriatric Patients Undergoing Lower Extremity Orthopedic Surgery

Before surgery, patients are asked to fast so the stomach is empty and stomach contents cannot enter the lungs during anesthesia. Long fasting is uncomfortable and can raise blood sugar and stress responses in older adults. Giving a carbohydrate drink up to 2 hours before surgery is part of enhanced recovery (ERAS) programs. It is not clear whether a maltodextrin drink or sugar water leaves less fluid in the stomach of older patients.

This randomized, double-blind study enrolls patients aged 60 years and older who are having elective lower limb orthopedic surgery under spinal or epidural anesthesia at Prof. Ngoerah General Hospital in Denpasar, Indonesia. Participants are assigned by chance to drink 400 mL of either a maltodextrin carbohydrate drink or sugar water 2 hours before anesthesia. The amount of fluid in the stomach is measured with bedside ultrasound before the drink and 2 hours after it. Blood glucose is measured before the drink, 2 hours after it and 6 hours after surgery. The neutrophil-lymphocyte ratio, a blood marker of inflammatory stress, is compared before surgery and 6 hours after surgery.

The results are intended to show which drink is better suited to older surgical patients and to support safer and more comfortable fasting practice.

Descripción general del estudio

Descripción detallada

Design. Double-blind, parallel-group randomized controlled trial with two arms and a 1:1 allocation ratio. Participants are recruited consecutively and allocated by computer-assisted block randomization. Setting: Central Surgical Installation and inpatient wards, Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali.

Procedure. Eligible patients are selected from the elective operating list the day before surgery and give written informed consent. All patients fast from solid food for 6 hours. In the reception area, age, sex, height, weight, body mass index, last meal and fasting duration are recorded. Baseline gastric ultrasound (right lateral decubitus, curvilinear probe) and capillary blood glucose are measured, and a blood sample for neutrophil and lymphocyte counts is taken. The participant then drinks 400 mL of the assigned drink within 15 to 30 minutes, 2 hours before anesthesia. Two hours later gastric ultrasound and blood glucose are repeated by the same operator. Anesthesia is neuraxial: spinal bupivacaine heavy 0.5% 10 to 12.5 mg at L3-L4, or epidural bupivacaine up to 0.25% in 10 to 12 mL. Six hours after the end of surgery, blood glucose and a complete blood count are repeated. Surgery type, duration and blood loss are taken from the electronic medical record.

Masking. The drinks are served in identical, opaque, unbranded, closed containers labeled A or B, with the same volume, temperature and timing, and drunk through a straw. The participant, the ultrasound operator who collects the data, and the data analyst do not know the allocation. The person who prepares and hands over the drinks knows it. The drinks differ in taste and appearance, so masking of participants relies on the opaque containers.

Hypothesis. The primary hypothesis is one-sided: gastric volume 2 hours after the maltodextrin drink is lower than after sugar water. The hypotheses for blood glucose and neutrophil-lymphocyte ratio are two-sided.

Sample size. The planned sample is 62 participants (31 per arm). The calculation used blood glucose as the driving outcome (28 per group, alpha 0.05, power 80%) plus 10% allowance for dropout.

Safety. Adverse events (allergy, nausea, bloating, regurgitation, hypotension, bradycardia) are managed by the anesthesia team, recorded, and reported to the hospital patient safety committee and the ethics committee.

Analysis. Normality is tested with Kolmogorov-Smirnov and variance homogeneity with Levene. Two groups are compared with the independent t-test or Mann-Whitney test. Repeated measurements use repeated-measures ANOVA or the Friedman test. Confounders are examined by stratification and a general linear model. Software: IBM SPSS Statistics 29.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

62

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Bali
      • Denpasar, Bali, Indonesia, 80114
        • Reclutamiento
        • Prof. Dr. I.G.N.G. Ngoerah General Hospital (RSUP Prof. Dr. I.G.N.G. Ngoerah)
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

60 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 60 years or older with adequate cognitive function on brief cognitive screening
  • ASA physical status II or III
  • Elective lower extremity orthopedic surgery under neuraxial anesthesia

Exclusion Criteria:

  • Emergency or urgent surgery
  • Unstable hemodynamics
  • Diagnosed gastrointestinal tract pathology
  • History of bariatric surgery
  • Dressing, wound cover or corset over the abdomen that prevents gastric ultrasound
  • Use of a proton pump inhibitor, H2 antagonist or drug affecting gastrointestinal motility (for example metoclopramide, loperamide) in the past week
  • Unable to lie in the lateral decubitus position
  • Body mass index below 19 or 35 kg/m2 and above
  • Refuses to take part after informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Maltodextrin Carbohydrate Loading

Participants drink 400 mL (4 packs of 100 mL) of a ready-to-drink clear maltodextrin carbohydrate beverage (Maltodex, about 200 kcal) within 15 to 30 minutes, 2 hours before anesthesia, after 6 hours of fasting from solid food. The drink is served in an opaque coded container with a straw.

400 mL (4 x 100 mL) of ready-to-drink clear maltodextrin beverage (Maltodex, PT Finusoprima Farma Internasional). Per 100 mL: 50 kcal, 13 g carbohydrate of which 4 g sugars, 15 mg sodium, vitamin A and zinc at 15% of daily value each. Single dose, drunk within 15 to 30 minutes, 2 hours before anesthesia. Unlike the comparator it contains added vitamin A and zinc.

Otros nombres:
  • Maltodex
Comparador activo: Sugar Water Carbohydrate Loading

Participants drink 400 mL of clear sugar water made with about 50 g of sucrose (table sugar) in drinking water (about 200 kcal) within 15 to 30 minutes, 2 hours before anesthesia, after 6 hours of fasting from solid food. The drink is served in an opaque coded container with a straw, identical to the other arm.

400 mL of clear solution prepared by the hospital nutrition installation by dissolving about 50 g of sucrose (table sugar) in drinking water to a final volume of 400 mL (about 200 kcal, no fat, no protein). Single dose, drunk within 15 to 30 minutes, 2 hours before anesthesia.

Otros nombres:
  • Solución de sacarosa

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Gastric volume 2 hours after carbohydrate loading
Periodo de tiempo: 2 hours after finishing the study drink, before anesthesia

Gastric volume in mL estimated from bedside antral ultrasound in the right lateral decubitus position using the Perlas formula: volume (mL) = 27.0 + 14.6 x right-lateral antral cross-sectional area (cm2) - 1.28 x age (years). One operator, blinded to allocation.

2 hours after finishing the study drink, before anesthesia

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in blood glucose from before loading to 2 hours after loading
Periodo de tiempo: Before the drink and 2 hours after the drink

Capillary blood glucose in mg/dL measured with an Accu-Chek glucometer before the drink and 2 hours after it.

Before the drink and 2 hours after the drink
Change in neutrophil-lymphocyte ratio from before surgery to 6 hours after surgery
Periodo de tiempo: Last preoperative sample and 6 hours after the end of surgery

Neutrophil-lymphocyte ratio calculated from the complete blood count differential (Sysmex XN-3000) of the last preoperative sample and a sample taken 6 hours after the end of surgery.

Last preoperative sample and 6 hours after the end of surgery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Tjahya Aryasa, Sp.An-TI, Subsp.An.O.(K), Rumah Sakit Umum Pusat Sanglah Denpasar
  • Silla de estudio: I Made Prema Putra, Sp.An-TI, Rumah Sakit Umum Pusat Sanglah Denpasar
  • Investigador principal: Lalu Reza Aldira Akbar, MD, Rumah Sakit Umum Pusat Sanglah Denpasar

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de septiembre de 2026

Finalización primaria (Estimado)

17 de noviembre de 2026

Finalización del estudio (Estimado)

30 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

5 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

9 de octubre de 2026

Publicado por primera vez (Actual)

14 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir